Paris, August 29, 2007 – The Board of Directors of Ipsen (Euronext: IPN), chaired by Jean-Luc Belingard, met August 28, 2007 to stop the accounts of the first half of 2007 published today. The interim financial report in respect of regulated information, is available on the website of the Group, investor relations section..

Commenting on the performance of the first half of 2007, Jean-Luc Belingard, President of the Ipsen Group, stated: The Group’s performance for the first half of 2007 are consistent with our expectations. Despite a difficult environment, marked by sharp price declines and increased competition, the Group has maintained a strong growth in sales. Our financial results for the six months, fully in line with the objectives ads, reflect our major strategic decisions, including pursuing an active policy of investment in Research and Development and the creation of a platform Endocrinology United States. These decisions are now fully validated by our news: we continue to achieve these goals the last few months our keys for the future development of the Group, first and foremost to obtain the authorization for the operation of Increlex ?’?® in Europe. We also carry the launch of Adrovance (TM) in France, has completed the clinical trial of Dysport ?’?® in spasmodic torticollis in the United States and gives up Ginkor Fort ?’?® in France to a specialist OTC sales. In this context, we are thus able to confirm our objectives and believe we can offset the decline in 2007 prices in France Tanakan ?’?® implementation on 1 July 2007. The foundations to accelerate growth are now on Ipsen strengthened, and we look with confidence the second half, which is rich in events including the concretization of our business alliance with Tercica, through the planned launch of Increlex ?’?® in Europe and the expected approval of Somatuline ?’?® in the United States.


.